BAX, BCL2 associated X, apoptosis regulator, 581

N. diseases: 420; N. variants: 9
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0002726
Disease: Amyloidosis
Amyloidosis
0.020 Biomarker disease BEFREE Molecular studies revealed that LLI treatment: (1) restored mitochondrial dynamics, by altering fission and fusion protein levels thereby suppressing -induced extensive fragmentation; (2) suppressed -induced collapse of mitochondrial membrane potential; (3) reduced oxidized mitochondrial DNA and excessive mitophagy; (4) facilitated mitochondrial homeostasis via modulation of the Bcl-2-associated X protein/B-cell lymphoma 2 ratio and of mitochondrial antioxidant expression; (5) promoted cytochrome c oxidase activity and adenosine triphosphate synthesis; (6) suppressed -induced glucose-6-phosphate dehydrogenase and nicotinamide adenine dinucleotide phosphate oxidase activity; (7) enhanced the total antioxidant capacity of hippocampal CA1 neurons, whereas reduced the oxidative damage; and (8) suppressed -induced reactive gliosis, inflammation, and tau hyperphosphorylation. 27815990 2017
CUI: C0002726
Disease: Amyloidosis
Amyloidosis
0.020 AlteredExpression disease BEFREE Compared with the treated group, the (+) borneol treated group significantly increased Bcl-2 expression with decreased expression of Bax. 23134284 2013